Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin vs Heparin in ECMO
NCT03707418Phase 1Withdrawn
- Sponsor
- Johns Hopkins University
- Start
- Apr 2021
- Primary completion
- Jun 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bivalirudin in thrombosis (2 arms), sponsored by Johns Hopkins University. Primary endpoints: Number of heparin-induced thrombocytopenia (HIT) events at 30 days, Number of Cross-overs between arms at 30 days and 7 more. Planned start Apr 2021; status: withdrawn.
02
Drugs
bivalirudin
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT03707418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03707418.